We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-19.74%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2B
AUM Growth
+$181M
Cap. Flow
-$182M
Cap. Flow %
-9.13%
Top 10 Hldgs %
62.34%
Holding
416
New
102
Increased
87
Reduced
79
Closed
120

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$21.3M
2
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$21.2M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$16.1M
4
BIIB icon
Biogen
BIIB
+$9.79M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$8.84M

Top Sells

Rank Stock Value
1
IWM icon
iShares Russell 2000 ETF
IWM
+$33.1M
2
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$7.45M
3
MBLY
Mobileye N.V.
MBLY
+$7.26M
4
TBRA
Tobira Therapeutics, Inc. Common Stock
TBRA
+$5.86M
5
ASXC
Asensus Surgical, Inc.
ASXC
+$5.01M

Sector Composition

Rank Sector Weight
1 Healthcare 11.94%
2 Consumer Staples 0.06%
3 Industrials 0.04%
4 Technology 0.04%
5 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SVRA icon
151
Savara
SVRA
$1.13B
$1.06M 0.05%
+55,391
New +$1.28M
INSM icon
152
PUT
Insmed
INSM
$23.2B
$977K 0.05%
771
-99
-11% -$1.3K
RGLS
153
DELISTED
Regulus Therapeutics
RGLS
$970K 0.05%
1,167
-583
-33% -$464K
LRMR icon
154
CALL
Larimar Therapeutics
LRMR
$416M
$966K 0.05%
121
+39
+48% +$3.08K
MNKD icon
155
CALL
MannKind Corp
MNKD
$1.28B
$966K 0.05%
1,200
-5,907
-83% -$33.8K
SAGE
156
CALL
DELISTED
Sage Therapeutics
SAGE
$939K 0.05%
293
+222
+313% +$7.82K
CASC
157
DELISTED
Cascadian Therapeutics, Inc.
CASC
$939K 0.05%
+123,167
New +$948K
WINT
158
DELISTED
Windtree Therapeutics Inc
WINT
$934K 0.05%
566,352
+42,099
+8% +$90.4K
TNXP icon
159
Tonix Pharmaceuticals
TNXP
$157M
– –
0
– –
ICPT
160
PUT
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$925K 0.05%
+72
New +$8.5K
QRHC icon
161
Quest Resource Holding
QRHC
$25.9M
$895K 0.04%
266,489
-37,891
-12% -$180K
RCKT icon
162
Rocket Pharmaceuticals
RCKT
$348M
$862K 0.04%
29,114
+7,201
+33% +$216K
ABEO icon
163
Abeona Therapeutics
ABEO
$345M
$855K 0.04%
13,364
+1,364
+11% +$90.3K
RXDX
164
DELISTED
Ignyta, Inc.
RXDX
$846K 0.04%
125,000
+70,901
+131% +$584K
TMBR
165
DELISTED
Timber Pharmaceuticals, Inc.
TMBR
$845K 0.04%
+52
New +$1.18M
ARLZ
166
DELISTED
Aralez Pharmaceuticals Inc.
ARLZ
$839K 0.04%
+236,364
New +$1.22M
TXMD icon
167
TherapeuticsMD
TXMD
$23.8M
$835K 0.04%
+2,608
New +$890K
TBRA
168
DELISTED
Tobira Therapeutics, Inc. Common Stock
TBRA
$818K 0.04%
100,000
-777,342
-89% -$5.86M
ACHN
169
DELISTED
Achillion Pharmaceuticals
ACHN
$816K 0.04%
+105,648
New +$774K
SGMO
170
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$814K 0.04%
134,500
+3,400
+3% +$20.4K
ARIA
171
CALL
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$808K 0.04%
+1,265
New +$7.09K
CYNA
172
DELISTED
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
$792K 0.04%
66,522
+7,912
+13% +$106K
EYPT icon
173
EyePoint Inc
EYPT
$1.02B
$787K 0.04%
+29,359
New +$928K
ACHN
174
PUT
DELISTED
Achillion Pharmaceuticals
ACHN
$776K 0.04%
+1,005
New +$7.36K
WGBS
175
DELISTED
WaferGen Bio-systems, Inc.
WGBS
$765K 0.04%
239,094
-37,121
-13% -$119K
5 6
7
8 9

Similar funds

NA
Novus Advisors Greenville, South Carolina $44.7M AUM 18.41% 1-Year Est. Return
CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

Sabby Management's Q1 2016 Portfolio in Review

As of Q1 2016, Sabby Management held 416 positions worth $2B, up 9.9% from $1.82B the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Sabby Management withdrew a net $182M in Q1 2016, closing 120 positions and reducing 79 holdings. Its most notable exit was iShares Russell 2000 ETF, an estimated $33.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 12% of assets, up from 10% a quarter earlier, followed by Consumer Staples and Industrials.

Against the trend, Sabby Management opened a new position in Amgen worth $21.5M.

  • Sabby Management's largest Q1 2016 buy was Amgen: 143,486 shares worth $21.5M.
  • Sabby Management added most to Northwest Biotherapeutics, Inc. Common stock in Q1 2016, an estimated $4.73M increase.
  • Sabby Management's biggest Q1 2016 reduction was GW Pharmaceuticals Plc American Depositary Shares, cutting an estimated $7.45M.
  • Sabby Management fully exited iShares Russell 2000 ETF in Q1 2016, selling an estimated $33.1M.
  • Sabby Management's ten largest holdings make up 62% of its $2B portfolio in Q1 2016.
  • Sabby Management opened 102 new positions and closed 120 in Q1 2016.
  • Sabby Management's portfolio value rose 9.9% quarter-over-quarter to $2B.

Based on Sabby Management's 13F filing for Q1 2016, filed 13 May 2016.